Nav: Home

Tamoxifen stimulates breast cancer growth following alteration of estrogen receptor

June 03, 2004

Scientists have discovered that resistance to tamoxifen treatment can be mediated by a modification of the estrogen receptor. These results enhance the understanding of what underlies tamoxifen resistance in breast cancer and may eventually allow for earlier identification of resistant tumors, providing critical time to choose an alternative therapeutic strategy that is more likely to be effective.

Because nearly three-quarters of all breast cancers are stimulated by estrogen acting at functional estrogen receptors (ER+), they are most often treated with anti-estrogen compounds that inactivate the estrogen receptor. The most common of these is the drug tamoxifen. However, only about half of ER+ breast cancers successfully respond to treatment with tamoxifen, while the other half are resistant. When tamoxifen is used in advanced disease, resistance will eventually arise in all tumors, even if they were initially sensitive. It has been reported that tamoxifen-resistant breast tumors sometimes stop growing when tamoxifen is withdrawn. Dr. Rob Michalides and colleagues from the Department of Tumor Biology at The Netherlands Cancer Institute found that activation of the enzyme protein kinase A (PKA) induced tamoxifen resistance in breast cancer cells through a unique mechanism. PKA modified the estrogen receptor in such a way that although tamoxifen could still bind, it could no longer convert the receptor to an inactive form. Instead, it acted as an estrogen receptor activator and encouraged tamoxifen-resistant cancer cell growth. Using a genetic screening technique, the researchers showed that this mechanism was also operational in patients.

The findings indicate that PKA may be a critical determinant of how ER+ breast cancers respond to tamoxifen. "This is highly relevant for breast cancer patients, since tamoxifen might induce the opposite effect when PKA is activated, stimulating ER+ tumor growth instead of inhibiting it. Such patients should be identified and treated with other hormonal agents, such as aromatase inhibitors or with a pure anti-estrogen such as fulvestrant," explains Dr. Michalides.
Rob Michalides, Alexander Griekspoor, Astrid Balkenende, Desiree Verwoerd, Lennert Janssen, Kees Jalink2, Arno Floore, Arno Velds, Laura van 't Veer, and Jacques Neefjes: "Tamoxifen resistance by a conformational arrest of the Estrogen Receptor-alpha after PKA activation in breast cancer"

Published in Cancer Cell Online on 3 June 2004, DOI: 10.1016/j.ccr.2004.05.016. The article will appear in Cancer Cell, Volume 5, Issue 6, June 2004.

Cell Press

Related Breast Cancer Articles:

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
More Breast Cancer News and Breast Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...